Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Healthcare Biotechnology

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

Bullboard Posts

Post by Riverfolkon May 02, 2020 9:36am

153 Views

Post# 30979138

FDA approves Gilead -Remdesivir

'Remdesivir - 25% of patients receiving it have severe side effects, including multiple-organ dysfunction syndrome, septic shock, acute kidney injury and low blood pressure. Another 23% demonstrated evidence of liver damage on lab tests."

This is why I own Arch, they own Patents for Metablok a drug that potentially treats inflammation in the LUNG , KIDNEY and LIVER. With so many Big Pharma drug candidates with these side effects! Arch will be on the radar as a take out target, Big Pharma will want this science !

Bullboard Posts

Full Circle Lithium goes global with its battery fire-fighter